• Profile
Close

Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: The SCARLET randomized clinical trial

JAMA May 23, 2019

Vincent JL, et al. – In this investigation involving patients with sepsis-associated coagulopathy, researchers determined the impact of human recombinant thrombomodulin vs placebo on 28-day all-cause mortality. The study was completed by 800 of 816 randomized patients, who were included in the full analysis set. Overall, the administration of human recombinant thrombomodulin did not significantly reduce 28-day all-cause mortality vs placebo in patients with sepsis-associated coagulopathy.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay